Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCIPOTRIENE vs CALCITRIOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.
Calcitriol, the active form of vitamin D, binds to vitamin D receptors (VDR) in target tissues, modulating gene transcription. It increases intestinal calcium and phosphate absorption, enhances renal tubular reabsorption of calcium, and promotes bone mineralization by stimulating osteoblast activity.
Plaque psoriasis (FDA-approved),Psoriasis of the scalp (FDA-approved),Chronic plaque psoriasis (off-label),Psoriatic nails (off-label),Ichthyosis (off-label),Vitiligo (off-label)
Management of hypocalcemia in patients undergoing chronic renal dialysis,Secondary hyperparathyroidism in patients with chronic kidney disease not yet on dialysis,Hypoparathyroidism (post-surgical, idiopathic, or pseudohypoparathyroidism),Off-label: Vitamin D-dependent rickets type I and II, osteoporosis (as an adjunct)
Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.
0.25-0.5 mcg orally once daily, may increase by 0.25 mcg/day at 4-8 week intervals; maximum 2 mcg/day.
The terminal elimination half-life of calcipotriene is approximately 5–6 hours following topical application. Systemic clearance is rapid due to extensive hepatic metabolism, leading to minimal accumulation.
5–8 hours (terminal) in normal renal function; prolonged up to 18–24 hours in chronic kidney disease (CKD) due to reduced clearance.
Calcipotriene undergoes extensive hepatic metabolism via cytochrome P450 enzymes (mainly CYP3A4, CYP2D6, and CYP1A2) to inactive metabolites, which are excreted in feces and urine.
Primarily metabolized in the kidney and intestine via 24-hydroxylase (CYP24A1) to inactive metabolites (e.g., calcitroic acid). No major hepatic cytochrome P450 involvement.
Calcipotriene is rapidly metabolized in the liver to inactive metabolites; less than 1% of the dose is excreted unchanged in urine. Fecal excretion accounts for approximately 70% of the administered dose, primarily as metabolites, with about 16% excreted in urine.
Renal (fecal after biliary excretion of metabolites): ~10% unchanged in urine; ~70% as metabolites in feces via bile.
Calcipotriene is approximately 94% bound to plasma proteins, primarily albumin.
~99% bound to vitamin D-binding protein (DBP) and albumin.
Due to extensive tissue binding and lipophilicity, the apparent volume of distribution (Vd) is estimated to be >5 L/kg, indicating extensive distribution into tissues.
0.5–1.0 L/kg (indicates extensive tissue distribution, primarily to kidney, intestine, bone).
Systemic bioavailability after topical application is less than 1% when applied to normal skin (0.5–1.0%) and up to 5–6% when applied to psoriatic plaques due to increased permeability.
Oral: ~70% (rapidly absorbed from small intestine). Intravenous: 100%.
No adjustment required due to minimal systemic absorption.
GFR 15-59 m L/min: initial dose 0.25 mcg orally once daily; GFR <15 m L/min: avoid use or use with caution, dose adjustment not established.
No adjustment required due to minimal systemic absorption.
No specific guidelines for Child-Pugh; use with caution in severe hepatic impairment as calcitriol metabolism may be altered.
Children ≥2 years: apply 0.005% cream or ointment once daily, not exceeding 50 g per week. Safety and efficacy in children <2 years not established.
Neonates and children: initial 0.25 mcg orally once daily; may increase by 0.25 mcg at 2-4 week intervals as needed; maximum 2 mcg/day.
No specific geriatric adjustment; use caution due to increased risk of skin irritation and potential for reduced renal function.
Start at low end of dosing range (0.25 mcg once daily) due to possible decreased renal function; monitor serum calcium and phosphorus closely.
None.
None officially designated by FDA. However, excessive administration may lead to hypercalcemia, hypercalciuria, and hyperphosphatemia, with risk of soft tissue calcification and renal toxicity.
Hypercalcemia: Avoid exceeding recommended dose; monitor serum calcium, urine calcium, and serum phosphate in patients with renal impairment or when used with other vitamin D products.,Local skin reactions: Irritation, itching, erythema, burning; discontinue if severe.,Photosensitivity: Avoid excessive exposure to sunlight or artificial UV light.,Use on face, groin, or axillae may increase irritation.,Not recommended in patients with known disorders of calcium metabolism.
Hypercalcemia risk: avoid excessive dosing; monitor serum calcium, phosphate, and alkaline phosphatase regularly,Hypercalciuria: may cause nephrolithiasis; maintain adequate hydration,Digitalis toxicity: hypercalcemia increases risk; monitor cardiac status,Adynamic bone disease: excessive suppression of PTH in dialysis patients may lead to low bone turnover,Aluminum intoxication: concurrent use of aluminum-containing phosphate binders may increase toxicity
Hypercalcemia or evidence of vitamin D toxicity,Hypersensitivity to calcipotriene or any component of the formulation,Use on face, eyes, or mucous membranes
Hypercalcemia or evidence of vitamin D toxicity,Hypersensitivity to calcitriol or any component of the formulation,Hyperphosphatemia (unless adequately managed)
No specific food interactions. Maintain adequate calcium and vitamin D intake as per normal dietary recommendations. Avoid high-dose calcium or vitamin D supplements unless prescribed, as additive hypercalcemic risk.
High dietary calcium intake may increase risk of hypercalcemia; advise consistent calcium intake per healthcare provider. No specific restrictions with other foods.
Pregnancy Category C. Systemic exposure is minimal with topical use, but animal studies have shown fetal abnormalities at high doses. No adequate human studies; risk cannot be ruled out. First trimester: insufficient data; second and third trimesters: avoid unless clearly needed. Topical application at recommended doses is unlikely to cause harm, but caution advised.
Calcitriol is the active form of vitamin D. At therapeutic doses, no increased risk of major malformations has been consistently demonstrated. However, excessive doses (hypercalcemia) during pregnancy can lead to fetal hypercalcemia, aortic stenosis, retinopathy, and intellectual disability. First trimester: No clear teratogenicity at normal doses. Second and third trimesters: Maternal hypercalcemia from overdosage may cause fetal hypercalcemia and adverse effects. Avoid doses causing maternal serum calcium >11 mg/d L.
Excretion into breast milk unknown. Topical calcipotriene has low systemic absorption; however, avoid application to breast area to prevent infant ingestion. M/P ratio not available. Use with caution in nursing mothers only if clearly needed.
Calcitriol is present in breast milk in low concentrations. The M/P ratio is approximately 0.3–0.4. At maternal therapeutic doses, risk to the infant is minimal. Monitor infant serum calcium if maternal high doses are used.
No dose adjustment required for topical use as systemic absorption is minimal. However, limit use to small areas to minimize cumulative exposure. No pharmacokinetic studies in pregnancy indicate need for dose change.
Pregnancy may increase vitamin D metabolism; however, calcitriol dose adjustments are generally not required for normal pregnancies. In cases of maternal hypoparathyroidism or renal disease, dosing may need adjustment based on serum calcium levels, as increased maternal blood volume and renal clearance may decrease calcitriol levels. Titrate to maintain normocalcemia.
Calcipotriene is a synthetic vitamin D3 analog used primarily for plaque psoriasis. It works by inhibiting keratinocyte proliferation and promoting differentiation. Avoid use on the face, intertriginous areas, and anogenital region due to irritation risk. Maximum weekly dose should not exceed 100 g to avoid hypercalcemia. Use with caution in patients with renal impairment or known hypercalcemia. Combination with topical corticosteroids can enhance efficacy and reduce irritation.
Monitor serum calcium and phosphate levels regularly; hypercalcemia risk especially with thiazide diuretics or high calcium intake. Calcitriol has a rapid onset (hours) and short half-life, making it ideal for acute management of hypocalcemia. Avoid concurrent use of magnesium-containing antacids due to risk of hypermagnesemia.
Apply a thin layer to affected areas only, avoiding healthy skin.,Wash hands after application unless treating hands.,Do not use on the face, groin, or skin folds unless specifically directed.,Do not exceed 100 grams per week to avoid side effects.,Avoid excessive sun exposure or tanning beds during treatment.,Inform your doctor if you experience signs of high calcium: nausea, vomiting, constipation, muscle weakness.,Use exactly as prescribed; do not use occlusive dressings unless instructed.,May cause local skin irritation; report severe reactions to your doctor.
Take exactly as prescribed, usually once daily with or without food.,Do not take additional calcium or vitamin D supplements without consulting your doctor.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, muscle weakness, confusion, or irregular heartbeat.,Avoid excessive intake of calcium-rich foods (e.g., dairy products) unless advised.,Store at room temperature away from light and moisture.
No interactions on record
"Dexamethasone, a potent glucocorticoid, induces the expression of the enzyme 24-hydroxylase (CYP24A1), which accelerates the catabolism of calcitriol (1,25-dihydroxyvitamin D3) into inactive metabolites. This reduces the bioavailability and therapeutic efficacy of calcitriol, potentially leading to inadequate control of hypocalcemia in patients with chronic kidney disease or hypoparathyroidism. Clinically, this interaction may manifest as declining serum calcium levels or worsening bone mineral density despite calcitriol therapy."
"Calcitriol, the active form of vitamin D, may reduce the serum concentration of aripiprazole through a proposed mechanism involving induction of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (P-gp) efflux transporter. This interaction could lead to decreased systemic exposure of aripiprazole, potentially compromising its antipsychotic efficacy. Clinically, patients may experience worsening of psychotic symptoms or require dose adjustments of aripiprazole when coadministered with calcitriol."
"Calcitriol, the active form of vitamin D, may inhibit the metabolism of delavirdine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), by competing for or downregulating cytochrome P450 (CYP) enzymes, particularly CYP3A4. This can lead to elevated delavirdine plasma concentrations, increasing the risk of dose-related adverse effects such as hepatotoxicity, rash, and central nervous system toxicity. Clinically, patients may experience enhanced delavirdine toxicity without a corresponding increase in antiretroviral efficacy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCIPOTRIENE vs CALCITRIOL, answered by our medical review team.
CALCIPOTRIENE is a Vitamin D Analog that works by Calcipotriene is a synthetic vitamin D3 analogue that binds to vitamin D receptors (VDR) in keratinocytes, inhibiting cell proliferation and promoting differentiation. It also modulates immune responses by reducing cytokine production.. CALCITRIOL is a Vitamin D Analog that works by Calcitriol, the active form of vitamin D, binds to vitamin D receptors (VDR) in target tissues, modulating gene transcription. It increases intestinal calcium and phosphate absorption, enhances renal tubular reabsorption of calcium, and promotes bone mineralization by stimulating osteoblast activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCIPOTRIENE and CALCITRIOL depend on the specific clinical indication. These are both Vitamin D Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCIPOTRIENE is: Apply a thin layer of 0.005% ointment, cream, or solution to affected areas once or twice daily. Maximum 100 g per week.. The standard adult dose of CALCITRIOL is: 0.25-0.5 mcg orally once daily, may increase by 0.25 mcg/day at 4-8 week intervals; maximum 2 mcg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCIPOTRIENE and CALCITRIOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCIPOTRIENE is classified as Category C. Pregnancy Category C. Systemic exposure is minimal with topical use, but animal studies have shown fetal abnormalities at high doses. No adequate human studies; risk cannot be rule. CALCITRIOL is classified as Category A/B. Calcitriol is the active form of vitamin D. At therapeutic doses, no increased risk of major malformations has been consistently demonstrated. However, excessive doses (hypercalcem. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.